Harwin Peter Evan
SEC CIK 1663607 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CBIO | CRESCENT BIOPHARMA, INC. | Dir, 10% | 2.75M | $18.24M | — | 1 | 2025-12-04 | 2025-12-04 |
| ZBIO | Zenas BioPharma, Inc. | Dir | 2.21M | $11.11M | — | 3 | 2024-09-16 | 2025-10-07 |
| SYRE | Spyre Therapeutics, Inc. | Dir | 4.02M | — | — | 1 | 2024-04-25 | 2024-04-25 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | Dir, 10% | 1.93M | $336.3K | — | 1 | 2023-09-29 | 2023-09-29 |
Most active insiders at CBIO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Harwin Peter Evan | Dir, 10% | $18.24M | — |
| 2 | Fairmount Funds Management LLC | Dir, 10% | $12.38M | — |
| 3 | Brumm Joshua T | CEO, Dir | — | $920.8K |
| 4 | McNeill Jonathan | Pres, COO | — | $446.9K |
| 5 | Pinkas Jan | CSO | — | $34.9K |
| 6 | Im Ellie Eunkyung | Chief Medical Off | — | $33.1K |
| 7 | Bispham Barbara Harlin | See Remarks | — | $33.0K |
| 8 | Scalzo Richard William | CFO | — | $30.2K |
| 9 | Lynch Ryan | See Remarks | — | $12.7K |
| 10 | Doughty Christopher Grant | Chief Business Off | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-12-08 | 2025-12-04 | CBIO | CRESCENT BIOPHARMA, INC. | Harwin Peter Evan | Dir, 10% | P - Purchase | $13.41 | +1.36M | 2.75M | +98% | +$18.24M |
| I | 2025-10-09 | 2025-10-07 | ZBIO | Zenas BioPharma, Inc. | Harwin Peter Evan | Dir | P - Purchase | $19.00 | +316.2K | 2.21M | +17% | +$6.01M |
| DMI | 2024-09-16 | 2024-09-16 | ZBIO | Zenas BioPharma, Inc. | Harwin Peter Evan | Dir | C - Cnv Deriv | — | +1.30M | 41.1K | New | — |
| DI | 2024-09-16 | 2024-09-16 | ZBIO | Zenas BioPharma, Inc. | Harwin Peter Evan | Dir | P - Purchase | $17.00 | +300.0K | 1.60M | +23% | +$5.10M |
| DI | 2024-04-25 | 2024-04-25 | SYRE | Spyre Therapeutics, Inc. | Harwin Peter Evan | Dir | M - OptEx | $0.00 | +3.64M | 4.02M | +962% | $0 |
| I | 2023-10-03 | 2023-09-29 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Harwin Peter Evan | Dir, 10% | P - Purchase | $13.63 | +24.7K | 1.93M | +1% | +$336.3K |
Purchase Sale Sale after option exercise All abbreviations